The complexity of R&D projects and growing international competition are fa
ctors leading to more cooperation especially among small and medium-sized f
irms. But even large integrated firms are often not willing or able to perf
orm the necessary amount of R&D and to cope with the uncertainty associated
with radical innovations.
In a virtual company, members form a network, thereby enabling projects to
be pursued by combining member's resources. Specific assets of a virtual co
mpany are its flexibility and ability to handle variety. Costs of co-ordina
tion and motivation are lowered if the virtual company succeeds in building
trust and commitment. On the other hand, lack of these pose severe problem
s.
In markets with a strong scientific-technological basis and rapid rate of c
hange the concept of a virtual organization seems appealing. High R&D costs
and risks can be shared, developments and time-to-market can be accelerate
d and the partners can concentrate on their respective core competencies.
In the paper we use an example from the biotechnology industry as a case st
udy and discuss some of the theoretical and practical problems that are enc
ountered in the virtual enterprise.